Acetazolamide for Treatment Resistant Schizophrenia

Recruiting now · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Schizophrenia, Schizo Affective Disorder

In brief

This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.

Key facts

Study ID

NCT04887792

Run by

Vishwajit Nimgaonkar, MD PhD

People needed

60

Starts

2022-02-01

Expected to finish

2028-06-30

Last updated by the study team

2026-07-07

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent.
• Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose).
• PANSS total score > 60 and Score > 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions.
• Stable dose of antipsychotic drug (APD) for > 1 month, continued throughout the study.
• Not participating in another randomized controlled clinical trial (RCT).

You may not qualify if…

• Substance abuse in the past month/dependence past 6 months with the exception of methadone prescribed for opiate withdrawal.
• History or current medical/neurological illnesses that may lead to unstable course, e.g., epilepsy.
• Pregnancy.
• Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease/adrenal failure; chronic closed angle-closure glaucoma.
• Current or prior treatment with ACZ or history of hypersensitivity to ACZ.
• Intellectual disability as defined in DSM 5.

Where it is running

• University of Pittsburgh — Pittsburgh, Pennsylvania, United States (enrolling)
• St John's Medical College Hospital — Bangalore, India (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.